Trial Profile
A retrospective,non interventional,multicenter study to evaluate efficacy and safety of Ombitasvir/paritaprevir/ritonavir with and without Dasabuvir Coadministered with and without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus coinfection with chronic kidney disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2017
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms Vie-KinD
- 04 Jul 2017 New trial record